| ²é¿´: 1684 | »Ø¸´: 6 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õßlixiongwap½«ÔùËÍÄú 20 ¸ö½ð±Ò | ||
lixiongwapгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÈËÌå·çÏÕÆÀ¹ÀÔõôд£¿
|
|
|
ÎÒ×öµÄÊÇÒ»ÖÖ»·¾³¶¾Î±à¼µÄÒâ¼ûÓÐÒ»Ìõ£¬ÒªÇóÔÚÌÖÂÛÖмÓÒ»¶ÎÒÔÎÒËùʹÓõĹàθ¼ÁÁ¿À´×öµÄ·çÏÕÆÀ¹À In addition, make sure that you add a risk assessment paragraph to the discussion in which you relate the dose levels used to (current) human exposure levels. This will help readers to judge the human relevance of your findings. ÇëÎÊÕâ¸ö¸ÃÔõôд£¿ÒªÐ´Ò»Ð©Ê²Ã´ÄÚÈÝ£¿Ð»Ð»´ó¼Ò£¡@Monash2011 |
» ²ÂÄãϲ»¶
¹ú×ÔÈ»ÆÀÉóÒâ¼û
ÒѾÓÐ12È˻ظ´
¹ú×ÔÈ»ÃæÉϸ´ÅÌ~»¶ÓÌÖÂÛ
ÒѾÓÐ14È˻ظ´
ϵͳ²é²»µ½
ÒѾÓÐ11È˻ظ´
ÓжàÉÙÈËÊǽñÌì²éϵͳ֪µÀ½á¹ûµÄ£¿
ÒѾÓÐ18È˻ظ´
Ϊʲô×ÊÖúÊý¸÷´ó¸ßУ¶¼´´Ð¸ߣ¬×Ô¼ºÉêÇëÔõô¾ÍÕâôÄÑ
ÒѾÓÐ12È˻ظ´
ÓÐûÓÐÈÔûÊÕµ½ÐÅÏ¢µÄ
ÒѾÓÐ3È˻ظ´
µ¼Ê¦Í²ۣºÎÒÔõô̯ÉÏÁËÕâô¸ö¼«Æ·Ñо¿Éú£¡
ÒѾÓÐ8È˻ظ´
»ù½ð²»ÖУ¬¹²Ãã
ÒѾÓÐ11È˻ظ´
Â鷳ר¼ÒÃÇ¿´¿´ÆÀίÃǵÄÒâ¼û£¨F¿ÚÃæÉÏ£©
ÒѾÓÐ9È˻ظ´
2026ÄêÒ¶ÆóËï»ù½ð
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
×ªÔØ£º×ª»ùÒòÖ²ÎïÓ°ÏìÈËÌ彡¿µµÄ¿ÉÄÜ·½Ê½
ÒѾÓÐ4È˻ظ´
ÍÁÈÀÎÛȾÁËÔõôÖÎÀí»¹ÔÄØ ÓÐÏà¹ØµÄÐмÒô
ÒѾÓÐ5È˻ظ´
¡¾×ªÌû¡¿»ùÒòרÀûÕ½Õù¡ª¡ª ¹Ù˾¡¢À§¾ÖÓëδÀ´
ÒѾÓÐ3È˻ظ´
¡¾×ªÌû¡¿»ùÒòרÀûÕ½Õù¡ª¡ª ¹Ù˾¡¢À§¾ÖÓëδÀ´
ÒѾÓÐ5È˻ظ´
|
2Â¥2017-08-17 21:59:04
|
3Â¥2017-08-18 08:33:58
|
4Â¥2017-08-19 09:39:52
|
5Â¥2017-08-19 15:21:36
|
6Â¥2017-08-20 00:21:08
|
7Â¥2017-08-20 07:48:07









»Ø¸´´ËÂ¥
ͶƱ:
10